ArticlePharmaceutical statistics
Accelerated Stability Studies: A Frequentist-Bayesian Hybrid Simulation Approach Implemented in the AccelStab R Package.
Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Stability assessment of vaccine drug products typically requires years of data collection. Accelerated stability studies offer a practical alternative by leveraging high-temperature data collected over shorter time periods. We model degradation using arbitrary nth order kinetics and derive a closed-form solution that enables extrapolation across time and temperature. We compare interval estimation methods including the delta method, bootstrap resampling, and Bayesian inference and propose a frequentist-Bayesian hybrid (FBH) posterior approximation framework based on a multivariate Student's t-distribution. FBH is closely related to objective Bayesian inference under noninformative priors in simple Gaussian settings and fully propagates uncertainty in both model parameters and residual variance. Simulation results show that FBH outperforms standard approaches by consistently achieving nominal coverage, particularly in small-sample settings where competing methods exhibit undercoverage. The approach provides well-calibrated confidence and prediction intervals while maintaining computational efficiency comparable to analytical methods and avoiding the cost of full posterior sampling. The methodology is illustrated using two vaccine development case studies and implemented in the AccelStab R package.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.